Mr. Billbäck will join from Essity where he was Senior Advisor following its acquisition of BSN Medical from the Swedish private equity group EQT in 2017. Prior to this, he was a member of the Group Executive Board/Management Committee at BSN Medical, where he held the position of Executive Vice President EMEA and Head of Global Commercial Operations. Mr. Billbäck spent over 13 years in senior management roles at BSN Medical, including Interim President of North America and Group Director Commercial Operations and R&D. BSN Medical develops, manufactures, markets and sells products within wound care, compression therapy and orthopedics.

Håkan Björklund, Chairman of BONESUPPORT, commenting on today’s announcement said: “I would like to thank Richard Davies for the significant contributions he has made to the company which have included an impressive growth of the business as well putting the company in a strong financial position following its IPO on Nasdaq Stockholm in June 2017.”

Emil Billbäck, commenting on his appointment said: “I am looking forward to becoming the CEO of BONESUPPORT. It is clear that the Company has an exciting future based on the significant growth potential of its current commercial products for the management of bone voids. These products, which are based on the Company’s highly differentiated CERAMENT platform, deliver important clinical and economic benefits to surgeons, patients and payers based on their ability to remodel to host bone and to elute antibiotics to protect the healing process by preventing infection. I also believe that BONESUPPORT’s pipeline, which is focused on novel products designed to enhance bone growth, will contribute to the Company’s longer term success.”